Spero Therapeutics Inc. (SPRO) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Spero Therapeutics Inc. (NASDAQ: SPRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.06 (-4.50% 1D, market cap $64.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, SPRO ranks #465 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRO carries a Roarable D- (43/100 RQD), trailing P/E of 7.5x, gross margin of —, and ROIC of 26.6%. By comparison, CPIX (Cumberland Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -16.4%, cap $65.2M) and GOSS (Gossamer Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $65.4M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
Per SPRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701108), Spero Therapeutics Inc. generated $12.6M in revenue (+3292.5% YoY), $8.6M in net income, and -$12.6M in free cash flow against $68.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 55% Net Buy • Disciplined Float (+0.24% YoY Shares)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
While SPRO currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.17) and Max Pain ($1.11) forces dealer call-delta covering toward $3.23.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Spero Therapeutics Inc. (SPRO) dropped -4.50% to $1.06, trading at 2% of its 52-week range ($1.04 – $3.08). Stretched risk/reward at 8x P/E (27% return on capital) under elevated 10-year interest-rate pressure.
Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
Analysts initiated coverage: Hold ALHC; Overweight/$6 SPRO; Buy/$3 LABT; Buy/$6 CLOV.
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Spero Therapeutics (NASDAQ:SPRO) with a Overweight rating and announces Price Target of $6.
Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapiesDae Gon Ha, Ph.D., appointed
Spero Therapeutics (NASDAQ:SPRO) plans to initiate a Phase II trial of its lead immunology candidate, SP001, in immunoglobulin G4-related disease, or IgG4-RD, in the second quarter of 2027, Chief Executive Officer Esther
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SPRO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SPRO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Spero Therapeutics Inc. (SPRO) ranks #465 by composite RQD confidence (43/100, grade D-) and #719 by equity capitalization ($64.6M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. RNTX currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with SPRO at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SPRO
ACTIVE
Spero Therapeutics Inc. | D- | 43/100 | 7.5x | — | 26.6% | -4.50% | $64.6M | Benchmark Subject |
| CPIX Cumberland Pharmaceuticals Inc. | D- | 38/100 | — | 85.0% | -16.4% | +7.82% | $65.2M | /cpix-vs-spro → |
| GOSS Gossamer Bio Inc. | E | 33/100 | — | — | -35.0% | -2.90% | $65.4M | /goss-vs-spro → |
| RNTX Rein Therapeutics Inc. | D | 49/100 | — | — | -35.0% | -7.79% | $62.7M | /rntx-vs-spro → |
| FBIO Fortress Biotech Inc. | D- | 39/100 | — | 66.9% | -35.0% | -4.00% | $66.7M | /fbio-vs-spro → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Spero Therapeutics Inc. (SPRO) reported GAAP revenue of $12.6M (+3292.5% vs. FY2024 revenue of $371.0K , and +1249.0% cumulative change since FY2023) , GAAP net income of $8.6M, operating cash flow of -$12.6M, and free cash flow of -$12.6M (+46.2% YoY). On the balance sheet, SPRO closed FY2025 with $68.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $12.6M | $8.6M | -$12.6M | -$12.6M | $68.9M | — |
| FY2024 (FY) | 2024-12-31 | $371.0K | -$68.6M | -$23.4M | -$23.4M | $110.5M | — |
| FY2023 (FY) | 2023-12-31 | $933.0K | $22.8M | -$33.0M | -$33.0M | — | — |
As of 2026-11-02, Spero Therapeutics Inc. (NASDAQ: SPRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.06 (-4.50% 1D, market cap $64.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, SPRO ranks #465 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRO carries a Roarable D- (43/100 RQD), trailing P/E of 7.5x, gross margin of —, and ROIC of 26.6%. By comparison, CPIX (Cumberland Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -16.4%, cap $65.2M) and GOSS (Gossamer Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $65.4M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
Per SPRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701108), Spero Therapeutics Inc. generated $12.6M in revenue (+3292.5% YoY), $8.6M in net income, and -$12.6M in free cash flow against $68.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
SPRO last traded at $1.06 (-4.50% on volume of 309,875 shares), positioning the stock -9.40% below its 50-day simple moving average ($1.17) and -46.46% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.04 to $3.08, SPRO sits at the 1.0% percentile with a 14-day RSI of 41.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($1.00 to $1.19).
Why SPRO Stock dropped -4.50% Today — RQD Quant Desk Flash. Stretched risk/reward at 8x P/E (27% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).